Letter to the Editor: Urges safety first with biosimilars
March 17, 2014
VP of Advocacy and Public Policy for the Arthritis Foundation, Heartland Region writes in about Illinois Senate Bill. Read more here.
Latest News
ASBM Files Comments to the FTC
March 1, 2014
The Alliance for Safe Biologic Medicines submitted comments to the Federal Trade Commission in regards to the “Follow-On Biosimilars Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition” hearing held in February. Read comments here.
Opinion Article “As prescription drugs advance, doctors need all the details”
February 1, 2014
Opinion piece by Dr. Sol De Jesus in the Lebanon Daily News. Read here.
Opinion Article “As prescription drugs advance, doctors need all the details”
February 1, 2014
Opinion piece by Dr. Sol De Jesus in the Lebanon Daily News. Read here.
New IfPA publication on why doctors need to know when pharmacists substitute biologics.
January 17, 2014
“The Physician’s Perspective: A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.
New IfPA publication on why doctors need to know when pharmacists substitute biologics.
January 17, 2014
“The Physician’s Perspective: A health policy brief from the Institute for Patient Access,” discusses the importance of a doctor’s need to know when their patients are switched to a biosimilar –- an issue public policy makers in the states are currently considering. Read more here.
ASBM Presents New European Survey Findings on Biosimilars and the Importance of Nonproprietary Naming
November 22, 2013
Dublin, Ireland – The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians’ views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. […]
Dr. Dolinar on WFAS AM Talk Radio
November 21, 2013
Dr. Dolinar discusses biosimilars with Seth Ginsberg of the Global Healthy Living Foundation on WFAS AM 1230 talk radio, Greater NYC. Listen here.
Dr. Dolinar Keynote at AfPA Working Group on Biologics, Chicago
November 15, 2013
The Alliance for Patient Access (AfPA) held their National Physicians Biologics Working Group Meeting on November 15-16 in Chicago, IL where Dr. Dolinar gave the keynote address to attending physicians. In his address, Dr. Dolinar discussed the current state of biosimilars and explained the disconnect between the science and potential policies and how they will impact […]
Dr. Dolinar Addresses State Legislators at NALEO Summit on Health
November 6, 2013
On October 26, Dr. Richard Dolinar served as the keynote luncheon speaker at the National Association of Latino Elected and Appointed Officials (NALEO) Legislative Summit on Health in Las Vegas. Dr. Dolinar discussed the science and policy issues surrounding biosimilar provisions of the Patient Protection and Affordable Care Act with state legislators from across the […]
